DGAP-News

STRATEC reports consistent growth in first nine months of 2014 - Seite 3

at its Beringen location in Switzerland. This measure, also scheduled for
2015, will boost the STRATEC Group's production capacity by around 20%.

To optimize structures, the key focus at the US location in Newbury Park
going forward will be on developing opto-mechanical components and
associated prototype construction.

Our partners, who generally market our systems together with their own
reagents, have currently reported only a very low level of impact related
to events in connection with the Ukraine crisis and sanctions on Russia. To
date, the only implications are a slight reduction in analyzer system
call-up volumes at one partner.

Based on budgets that account for acceptance volume forecasts from our
customers and market launches expected in the coming years, STRATEC
continues to expect average annual sales growth of 8% to 12% for the years
through to 2017 (based on the volume of sales generated in the 2013
financial year). Growth rates are expected to fluctuate between individual
years. For 2014, STRATEC continues to expect substantial sales growth
compared with the 2013 financial year; accompanied by a significant rise in
its EBIT margin.


Conversion in accounting methods

The business results presented here represent consolidated figures
following the previously announced amendment to accounting methods pursuant
to IAS 8 (Accounting Policies, Changes in Accounting Estimates and Errors).
The comparative figures for the previous year have been adjusted
accordingly. The amendments to accounting methods are explained in detail
in the 2013 Annual Report from Page 48 onwards.

Among other factors, these voluntary amendments also involved converting
the accounting method used to recognize projects, a measure resulting from
a recommendation made by the German Financial Reporting Enforcement Panel
(DPR) and whose implementation was completed at the end of 2013.


Interim Report as of September 30, 2014

Further details can be found in our Interim Report as of September 30,
2014, which has been published today on the company's homepage at
www.stratec.com/financial_reports.


About STRATEC

STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully
automated analyzer systems for its partners in the fields of clinical
diagnostics and biotechnology. These partners market such systems, in
general together with their own reagents, as system solutions to
laboratories, blood banks and research institutes around the world. The
company develops its products on the basis of its own patented
technologies.
Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard
segment of the Frankfurt Stock Exchange and are listed in the TecDAX select